ScripHong Kong-listed TYK Medicines has claimed TY-9591, its third-generation EGFR inhibitor, outperformed AstraZeneca’s same-class blockbuster Tagrisso (osimertinib) in the first-line treatment of brain m
ScripAmid a sweeping tightening of securities regulatory policies since late 2023, there has been a dearth of initial public offerings for bioventures in the Chinese mainland. But Hong Kong has just welcom